Audeara Limited has raised $1.26 million through a two-tranche share placement to back its expanding technology licensing and retail channels, following a year of revenue growth and reduced cash burn.
- Placement raises $1.26 million via 38.18 million shares
- FY26 revenue up 20% to $4.4 million with 50% tech growth
- Board commits $275,000, tranche two needs shareholder approval
- Funds to support licensing, inventory, and cashflow sustainability
- Options issued exercisable at 6.5 cents expiring in two years
Capital Raise Supports Commercial Momentum
Audeara Limited (ASX:AUA) has locked in firm commitments to raise $1.26 million through a share placement priced at 3.3 cents per share, slightly above its recent trading average. The raise involves issuing 38.18 million new shares in two tranches, accompanied by free-attaching options exercisable at 6.5 cents over two years. This capital injection aims to accelerate Audeara’s commercial growth and help the company target operating cashflow sustainability in the 2027 financial year.
Strong FY26 Performance Underpins Fundraising
The placement follows a year of improved operating metrics, with unaudited FY26 revenue reaching approximately $4.4 million, a 20% increase year-on-year. Notably, revenue from Audeara’s technology licensing segment surged 50% to $1.68 million. Operating cash outflows narrowed significantly to about $0.4 million, down from $1.7 million in FY25, reflecting tighter cost control and better cash management.
Board Participation and Shareholder Approval
Audeara’s board members have committed $275,000 to the placement, signaling confidence in the company’s trajectory. The first tranche, raising $755,000, will be issued under existing placement capacity, while the second tranche of $505,000 requires shareholder approval at the upcoming AGM scheduled for 24 November 2026. The company did not appoint a lead manager or advisor, and no material fees are associated with the placement.
Deployment of Funds and Strategic Focus
The fresh capital will support multiple facets of Audeara’s commercial strategy, including advancing AUA Technology licensing and engineering services, bolstering inventory across wholesale, international, retail, and partner channels, and providing working capital. Audeara’s products are now distributed in over 3,000 clinics globally, including around 1,500 in Australia, spanning 12 countries. This diversified footprint underpins the company’s growth ambitions.
Options Terms and Share Capital Impact
Each free-attaching option entitles the holder to one share at an exercise price of 6.5 cents, expiring two years from issue. If fully exercised, these options could dilute existing shareholders but also provide additional funding. Post-placement, Audeara will have roughly 219.1 million shares on issue, excluding any option conversions. The new shares will rank equally with existing shares from their issue date.
Chairman Highlights Strategic Flexibility
Chairman David Trimboli emphasised the placement’s role in enhancing Audeara’s flexibility to capitalise on emerging opportunities across technology and sales channels. He noted the company’s progress in revenue growth and cashflow reduction, describing the raise as a platform to sustain momentum while moving toward sustainable operating cashflow.
Bottom Line?
Audeara’s $1.26 million placement underpins its transition toward cashflow sustainability, but the success of tranche two hinges on shareholder approval later this year.
Questions in the middle?
- Will shareholders approve the second tranche at the November AGM?
- How will the market respond to potential dilution from option exercises?
- Can Audeara maintain its revenue growth and further reduce cash outflows in FY27?